drugset / Trial / NCT01690468
PTX-200 and Carboplatin in Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
Timeline
- Start
- 2014-09
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Triciribine | Unknown | 15 mg/m2 | Intravenous |
| Subject | Triciribine | Unknown | 25 mg/m2 | Intravenous |
| Subject | Triciribine | Unknown | 30 mg/m2 | Intravenous |
| Subject | Triciribine | Unknown | 35 mg/m2 | Intravenous |
| Subject | Triciribine | Unknown | 45 mg/m2 | Intravenous |